Clinical Trials · NCT00888082

Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy

Name: Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

WithdrawnPhase 3Gonadorelin

Phase: Phase 3
Recruitment status: Withdrawn
Sponsor: AstraZeneca
Enrollment: 102
Start date: Not specified
Locations: 3 sites, Turkey (Türkiye)
Primary endpoint: The ovarian function will be considered as regained, if E2 measurements return to premenopausal levels (equal to or above 20 pg/ml), FSH measurements return to premenopausal levels (less than or equal to 40 IU/L)

View Gonadorelin compound reference